Efficacy of omalizumab in delayed pressure urticaria: a case report.
Bindslev-Jensen
C
C
Department of Dermatology and Allergy Centre, Odense University Hospital, Odense C, Denmark. carsten.bindslev-jensen@ouh.regionsyddanmark.dk
Skov
P S
PS
D000328:Adult; D018926:Anti-Allergic Agents / Q000627:therapeutic use*; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001491:Basophils / Q000187:drug effects / Q000276:immunology; D005260:Female; D006636:Histamine Release / Q000187:drug effects; D006801:Humans; D000069444:Omalizumab; D010812:Physical Stimulation / Q000009:adverse effects; D014581:Urticaria / Q000188:drug therapy* / Q000209:etiology
D018926:Anti-Allergic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab